7 Biotechnology Stocks to Sell Now

Advertisement

This week, the ratings of seven Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Genomic Health (NASDAQ:GHDX) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. GHDX also rates an F in Portfolio Grader’s specific subcategory of Earnings Revisions. The stock has a trailing PE Ratio of 167.80. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock.

Acorda Therapeutics (NASDAQ:ACOR) earns a D this week, moving down from last week’s grade of C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

This is a rough week for Amarin (NASDAQ:AMRN). The company’s rating falls to D from the previous week’s C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. As of June 5, 2013, 18% of outstanding Amarin shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader.

Exelixis (NASDAQ:EXEL) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of June 5, 2013, 20.4% of outstanding Exelixis shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock.

Trius Therapeutics (NASDAQ:TSRX) is having a tough week. The company’s rating falls from a C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

Slipping from a C to a D rating, Discovery Laboratories (NASDAQ:DSCO) takes a hit this week. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For a full analysis of DSCO stock, visit Portfolio Grader.

This week, Achillion’s (NASDAQ:ACHN) rating worsens to a D from the company’s C rating a week ago. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of June 5, 2013, 12.8% of outstanding Achillion shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2013/06/7-biotechnology-stocks-to-sell-now-ghdx-acor-amrn-8/.

©2024 InvestorPlace Media, LLC